CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Clinical Trials Arena
High ImpactOriginal article

J&J’s Intra-Cellular buy continues to bear fruit with Caplyta bipolar win

CaplytaPositive
AI Analysis

Summary

J&J's 2025 acquisition of Intra-Cellular Therapies for $14.6bn, the largest pharma M&A deal that year, continues to deliver value with Caplyta showing positive results in bipolar disorder.

Importance:8/10
Sentiment:
0.70
M&AacquisitionCaplytabipolar disorderlargest pharma deal 2025
Related Companies

Read the original article

Published by Clinical Trials Arena on September 22, 2026 10:15 AM

Read Original